We’re proud to share that Dr. Art Hsing-Mao Chu, CEO of T-E Meds, will be presenting at the 4th World ADC Asia Summit, taking place June 10–12 in Incheon, South Korea.
Dr. Chu will share updates on our innovative tech platforms and drug candidates, with a special focus on our ADC technologies. He will present “Developing High-Efficacy, Stable Drug Bundle-Based ADCs with Optimized Dual Payload Combinations” covering:
- Dual Drug Bundles: Engineered for superior efficacy and resistance mitigation through strategic payload pairing.
- CHO-TEM ADC Technology: A mild, one-step enzymatic process introducing four azido groups via glycan modification, enabling the conjugation of four dual-payload drug bundles.
- High-DAR, Glyco-Engineered ADCs: Site-specific conjugation delivers ADCs that are both potent and stable
World ADC Asia, the premier ADC conference, gathers top industry leaders to discuss the future of ADC development. Join us as we share how our innovative Drug Bundle approach and glycoengineering platform are paving the way for the next generation of high-performance ADCs.
